Biogen (BIIB) has recently caught investor interest due to its
regulatory wins and new data. The European Medicines Agency supports high dose of
Nusinersen, which is positive opinion for the treatment of Spinal Muscular Atrophy. There is fresh data on subcutaneous initiation of
lecanemab, which will be shared at
CTAD 2025. Amid regulatory approvals and new data, the stock has seen ups and downs.
Dravet Syndrome study results and
Q3 earnings impacted the stock's valuation. New product growth is likely to reshape Biogen's investment outlook. Post the
Q3 earnings announcement, the stock experienced a one-time loss of $471M, raising doubts over the rebounding profit narrative. Recent pipeline and partnership developments and the Alcyone buyout have led to a revaluation of the stock.
Lecanemab, a medicine that slows the progression of early Alzheimer's disease, is now available in the U.S. It is also expecting an approval for
leqembi maintenance dosing in the UK, and the
Vanqua Bio licensing deal is expected to expand its immunology portfolio.
Biogen BIIB News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sat, 22 Nov 2025 18:24:01 GMT -
Rating 7
- Innovation 6
- Information 7
- Rumor -5
